Taylor O'Brien
Founder Chief Executive Officer@ aota.io
Santa Clara, California, United States
View Taylor O'Brien's Email
View Taylor O'Brien's Email & Phone
Real-Time AI Research
0 search queries left
FlashIntel GPT
Hello! I'm FlashIntel GPT, your personal AI search assistant. Feel free to ask me anything about Taylor O'Brien, and I'll do my best to assist you.
You

Tell me more about Taylor O'Brien?

FlashIntel GPT

Taylor O'Brien is a recovering startup founder with 19.7 years of experience. He is currently focused on OTC Pink Sheet Reverse Merger and heavily invested in BioTech/AI. Taylor is committed to preventing and eliminating infectious diseases in an endemic, pandemic, and syndemic states. He is the founder of Enzolytics, a biotechnology company that specializes in monoclonal antibodies targeting immutable epitope sites. Taylor's expertise lies in Enzolytics, a proprietary AI and mAb platform, and he is actively involved in the development of microbiome and other drug platforms. He is not a financial advisor but a shareholder and believes in the team, tech, mission, and
For inquiries about Phone Number and Email, please click here Unlock Contact

Research Details
Skills & Insights
Colleagues

Emails and Phone Numbers

@aota.io
@gmail.com
@waltersandwolf.com
View Emails and Phone Numbers
10 free lookups per month

About

Recovering startup founder - now - Investor/Trader focusing on OTC Pink Sheet Reverse Merger & heavily invested in BioTech/AI & the convergence of the two.The social cause & goal I am committed to & invested in is to cure & eradicate infectious diseases that exist in an endemic, pandemic, and syndemic states killing millions each year - such as hiv & covid - and ultimately prevent the next pandemic / make healthcare affordable and individualized as a one size fits all doesn’t work. Enzolytics ($enzc) is my primary holding since Sept 2020 & they have fully monoclonal antibodies which target immutable highly conserved epitope sites preventing virus escape and thus functions as a cure. This is done using their proprietary AI & mAb platform which is complimented by their partnerships with companies like Intel. Microbiome and other drug platforms like ITV1 immune modulator and other patents are in their pipeline and the recent announcement of a CDMO partnership to soon be announced (9/30/21) I am not a financial advisor but I am a shareholder and believer in their team, tech, mission, and vision of the future - I will post some due diligence on my page if you find yourself interested to invest or network with their scientists as you see fit. I haven’t lost my passion for Evolving age old industries through technology convergence, innovative business models, and IT Consumerization. For more information, please visit our website https://aota.io, or our LinkedIn Business Page.Will be returning to the entrepreneurial endeavors in the near future - during my startup experience I got a lot of life too like fracturing my spine and having to decide to stay open or lick my wounds when covid hit us all.Currently taking care of my health and possibly retiring off $enzc but I will never stop inventing or working as it’s my passion. Feel free to reach out.

...See More

Work Experience

San Jose, California, 95125, US

Construction

1
Show More

Taylor O'Brien's Professional Milestones

  • Intern - Instructional Designer For Companies Intranet And Jr. Project Manager (2007-06-01~2009-09-01): Developed and implemented high-quality instructional design programs to drive brand awareness and enhance user experience.
  • Intern - Instructional Designer For Companies Intranet And Junior Project Manager (2007-06-01~2009-09-01): Leading the design process, demonstrating proficiency in creating engaging instructional materials for companies intranet and junior project managers.
Show More

Education

California State University, Chico
California State University, Chico

Psychology,

Design,

Communication,

Bachelors,

Bachelor Of Arts,

Bachelor Of Science,

Instructional Design & Technology,

Communication Design Opt. Mass Communication

1136073600-1293840000
Show More